{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Romer TB"],"funding":["Kræftens Bekæmpelse","University of Copenhagen | Det Sundhedsvidenskabelige Fakultet, Københavns Universitet","The NEYE Foundation","Lundbeck Foundation"],"pagination":["1239-1250"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8548315"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["125(9)"],"pubmed_abstract":["<h4>Background</h4>Novel immunotherapies targeting cancer-associated truncated O-glycans Tn (GalNAcα-Ser/Thr) and STn (Neu5Acα2-6GalNacα-Ser/Thr) are promising strategies for cancer treatment. However, no comprehensive, antibody-based mapping of truncated O-glycans in tumours exist to guide drug development.<h4>Methods</h4>We used monoclonal antibodies to map the expression of truncated O-glycans in >700 tissue cores representing healthy and tumour tissues originating from breast, colon, lung, pancreas, skin, CNS and mesenchymal tissue. Patient-derived xenografts were used to evaluate Tn expression upon tumour engraftment.<h4>Results</h4>The Tn-antigen was highly expressed in breast (57%, n = 64), colorectal (51%, n = 140) and pancreatic (53%, n = 108) tumours, while STn was mainly observe"],"journal":["British journal of cancer"],"pubmed_title":["Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin."],"pmcid":["PMC8548315"],"funding_grant_id":["313-2019-869"],"pubmed_authors":["Groen A","Schnabel J","Wandall HH","Pedersen JW","Dabelsteen S","Romer TB","Aasted MKM","Tan E","Haue AD"],"additional_accession":[]},"is_claimable":false,"name":"Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin.","description":"<h4>Background</h4>Novel immunotherapies targeting cancer-associated truncated O-glycans Tn (GalNAcα-Ser/Thr) and STn (Neu5Acα2-6GalNacα-Ser/Thr) are promising strategies for cancer treatment. However, no comprehensive, antibody-based mapping of truncated O-glycans in tumours exist to guide drug development.<h4>Methods</h4>We used monoclonal antibodies to map the expression of truncated O-glycans in >700 tissue cores representing healthy and tumour tissues originating from breast, colon, lung, pancreas, skin, CNS and mesenchymal tissue. Patient-derived xenografts were used to evaluate Tn expression upon tumour engraftment.<h4>Results</h4>The Tn-antigen was highly expressed in breast (57%, n = 64), colorectal (51%, n = 140) and pancreatic (53%, n = 108) tumours, while STn was mainly observe","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-22T05:38:37.109Z","creation":"2025-04-05T21:26:25.784Z"},"accession":"S-EPMC8548315","cross_references":{"pubmed":["34526666"],"doi":["10.1038/s41416-021-01530-7"]}}